mucopolysaccharidosis

(redirected from Mucopolysaccharidosis VI)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Mucopolysaccharidosis VI: Maroteaux-Lamy syndrome

mucopolysaccharidosis

[¦myü·kō‚päl·ē‚sak·ə·rə′dō·səs]
(medicine)
Any of several inborn metabolic disorders involving mucopolysaccharides; the six types are MPS I, Hurler's syndrome; MPS II, Hunter's syndrome; MPS III, Sanfillipo's syndrome; MPS IV, Morquio's syndrome; MPS V, Scheil's syndrome; and MPS VI, Maroteaux-Lamy's syndrome.
References in periodicals archive ?
Clinical Trials by Phase 21 In Progress Trials by Phase 22 Clinical Trials by Trial Status 23 Clinical Trials by End Point Status 24 Unaccomplished Trials of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) 25 Subjects Recruited Over a Period of Time 27 Clinical Trials by Sponsor Type 28 Prominent Sponsors 29 Top Companies Participating in Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials 30 Prominent Drugs 31 Clinical Trial Profiles 32 Clinical Trial Overview of Top Companies 32 BioMarin Pharmaceutical Inc.
To order this report: Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome) Global Clinical Trials Review, H1, 2014 http://www.
Annualized market data for the Gaucher Disease Type 1, Niemann Pick Type C, Fabry Disease, Pompe Disease and Mucopolysaccharidosis VI Disease in the neurometabolic disorders market from 2002 to 2010, with forecasts to 2017.
5 Neurometabolic Disorders Market to 2017 - Mucopolysaccharidosis VI 73
7 Mucopolysaccharidosis VI Therapeutics Market Drivers 80
Table 58: Neurometabolic Disorders Market to 2017, Global, Mucopolysaccharidosis VI, Revenue ($m), 2002-2010 74
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution) for inflammatory conditions.
Aryplase (recombinant human arylsulfatase B) is an investigational enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI).
Nasdaq:BMRN) and (Swiss SWX New Market:BMRN), today announced that BioMarin began dosing patients last month in a Phase 2 clinical trial of Aryplase(TM) (recombinant human N-acetylgalactosamine 4-sulfatase or arylsulfatase B), an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI).

Full browser ?